{
    "title": "Eisai-Biogen Alzheimer's drug success follows many failures",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11256693/Eisai-Biogen-Alzheimers-drug-success-follows-failures.html",
    "date": "2022-09-27",
    "keywords": [
        "drug",
        "trial",
        "decline",
        "johnson",
        "treatment",
        "antibody",
        "brain",
        "prevent",
        "latestage",
        "bace",
        "inhibitor",
        "biogen",
        "inc",
        "disease",
        "company",
        "roche",
        "beta",
        "tau",
        "midstage",
        "co",
        "buildup",
        "committee",
        "ltd",
        "lecanemab",
        "win",
        "string",
        "memoryrobbing",
        "coverage",
        "medicare",
        "following",
        "list",
        "profile",
        "name",
        "outcome",
        "mechanism",
        "action",
        "crenezumab",
        "toxic",
        "protein",
        "plaque",
        "progression",
        "chance",
        "efficacy",
        "role",
        "ac",
        "immune",
        "gantenerumab",
        "combination",
        "solanezumab",
        "betaamyloid",
        "gene",
        "induce",
        "growth",
        "difference",
        "cell",
        "death",
        "merck",
        "amp",
        "verubecestat",
        "tomoderate",
        "study",
        "vs",
        "placebo",
        "enzyme",
        "development",
        "liver",
        "risk",
        "cnp520",
        "amgen",
        "banner",
        "institute",
        "function",
        "work",
        "round",
        "eisai",
        "discontinuation",
        "riskbenefit",
        "ratio",
        "reporting",
        "bhanvi",
        "satija",
        "raghav",
        "mahobe",
        "mishra",
        "bengaluru",
        "editing",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}